Chase Knickerbocker

David Amsellem

Christian Glennie

Paul Cuddon

Thibault Boutherin

Brandon Folkes

Brian Balchin

Carl Byrnes

Dennis Ding

- Indivior PLC intends to **redomicile from the U.K. to the U.S.**, establishing a new U.S. parent company, Indivior Pharmaceuticals, Inc. (IPI), above its existing U.K. parent company.  **[1625297_20251001PH87422:0]** 
- The proposed change aims to **maximize the benefits of its U.S. Nasdaq listing**, including expanding U.S. capital markets presence, increasing potential U.S. equity indexation, and simplifying corporate governance.  **[1625297_20251001PH87422:0]** 
- Shareholders of Indivior PLC will receive **one new IPI share for each Indivior PLC share held**, with IPI's common stock continuing to trade on Nasdaq under the symbol INDV.  **[1625297_20251001PH87422:0]** 
- The transaction is expected to become effective in **late January 2026**, following a shareholder vote at an Extraordinary General Meeting (EGM) in early December 2025.  **[1625297_20251001PH87422:0]**

Indivior Proposes U.S. Domiciliation

- Indivior PLC initiated the "Indivior Action Agenda" in **Q2 2025**, a **three-phased, multi-year operational roadmap** designed to maximize business potential and create shareholder value.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- On **August 26, 2025**, the company began implementing Phase 1 initiatives, which include **headcount reductions** and **real estate consolidations**, aimed at simplifying the organization and eliminating non-essential activities.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- These actions are expected to result in pre-tax restructuring charges of approximately **$39 to $50 million**, with **$27-$35 million** being cash, primarily recognized in **Q3 and Q4 2025**.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]**  These charges consist of **$16-$19 million** for employee severance, **$15-$22 million** for real estate consolidation, and **$8-$9 million** for consulting, legal, and tax planning.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- Indivior is also exploring strategic alternatives for its OPVEE® product and non-U.S. business.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]**

Indivior PLC Announces Indivior Action Agenda and Restructuring Charges

INDIVIOR (INDV)